Evidence map›Paper›PMID 40792441›Full record

ArticleAnnals of medicine2025

EpCAM-targeted near-infrared photoimmunotherapy (NIR-PIT) for the treatment of breast cancer.

Aki Furusawa, Seiichiro Takao, Motofumi Suzuki, Makoto Kano, Hiroshi Yamamoto, Miyu Kano, Peter Choyke, Hisataka Kobayashi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Aki FurusawaMolecular Imaging Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA.ORCID 0000-0002-1339-4219
Seiichiro TakaoMolecular Imaging Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA.
Motofumi SuzukiMolecular Imaging Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA.
Makoto KanoMolecular Imaging Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA.
Hiroshi YamamotoMolecular Imaging Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA.
Miyu KanoMolecular Imaging Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA.
Peter ChoykeMolecular Imaging Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA.
Hisataka KobayashiMolecular Imaging Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA.ORCID 0000-0003-1019-4112

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNear-infrared photoimmunotherapy (NIR-PIT) is a targeted cancer treatment that uses antibody-IR700 conjugates and selectively destroys cancer cells expressing a target antigen when exposed to near-infrared (NIR) light. NIR-PIT not only destroys targeted cancer cells but also induces anticancer immune activation. Currently, epidermal growth factor receptor (EGFR) is the only clinically approved target for NIR-PIT. To expand the therapeutic potential of this therapy, we investigated EpCAM as a potential target for NIR-PIT.

methodWe first evaluated the target cell-killing efficacy of EpCAM-targeted NIR-PIT (EpCAM-NIR-PIT) using the antibody Edrecolomab in human breast and colon cancer models characterized by high EpCAM expression. Next, we evaluated anticancer immune activity induced by EpCAM-NIR-PIT with an anti-PD-1 immune checkpoint inhibitor in a mouse breast cancer model in immunocompetent mice.

resultBoth

conclusionThis study demonstrated that EpCAM-NIR-PIT, particularly when combined with immune-activating agents such as anti-PD-1, is a promising new approach for cancer treatment, inducing durable and systemic anticancer immunity.

Indexed as

Breast NeoplasmsEpithelial Cell Adhesion MoleculeImmunotherapyPhototherapyAnimalsCell Line, TumorFemaleHumansImmune Checkpoint InhibitorsInfrared RaysMiceXenograft Model Antitumor AssaysEPCAM protein, humanEpithelial Cell Adhesion MoleculeImmune Checkpoint Inhibitorsbreast cancerCancerEpCAMnear-Infrared photoimmunotherapyNIR-PIT

Identifiers

PMID40792441
PMCPMC12344674

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.